High Throughput HPLC Analysis of Barbiturates Application Note

Total Page:16

File Type:pdf, Size:1020Kb

High Throughput HPLC Analysis of Barbiturates Application Note High Throughput HPLC Analysis of Barbiturates Application Note Forensic Toxicology Author Introduction John W. Henderson, Jr., Cliff Woodward, and Ronald E. Majors Although hundreds of barbiturates have been Agilent Technologies, Inc. synthesized over the past century, only about a 2850 Centerville Road dozen are used today. One factor deter-mining Wilmington, DE 19808-1610 which barbiturate is prescribed depends on the USA duration of its effectiveness. Duration of effect is determined by chemical struc- Abstract ture and this depends mainly on the alkyl groups attached to carbon #5 (see Figure 1) which confer In this study, an established HPLC method for USP Pheno- lipid solubility to the drug. The duration of effec- barbital was sequentially and quickly improved to a high tive action decreases as the total number of car- throughput method using Rapid Resolution (RR) and Rapid bons on C #5 increases. To be more specific, a long Resolution High Throughput (RRHT) techniques. New duration effect is achieved by a short chain and/or RRHT column technology is an especially powerful tool for phenyl group. A short duration effect occurs when improving lab productivity by reducing HPLC analysis time there are the many carbons and branches on the dramatically. Starting with a proven rugged method, alkyl chain [1]. conversion to a high throughput method can be achieved simply by replacing the original analytical-sized column Fast analysis of blood and/or other body fluids or with either a RR or RRHT column. The reasons for this hair can be useful in emergency situations. Figure direct conversion include the similar selectivity of smaller 1 lists the chemical structures of the barbiturates 1.8- and 3.5-µm particles compared to larger used in this study. 5-µm particles, and an engineered particle size distribu- tion that reduces unacceptably high system pressures that may be experienced with other sub-two micron packings. O O O CH CH CH HN NH 2 2 HN NH NH O O CH2CH CH2 O O CH3 O N O H R groups attached to the number 5 carbon atom Barbituric acid Phenobarbital Allobarbital CH3 O O CH2CHCH3 3CH N NH CH3 CH2CH CH2 OON OON H H Butalbital Hexobarbital Figure 1. Structures of barbiturates used in this study and barbituric acid. Start with a Proven HPLC Method They maintain column efficiency and resolution because the particle size decreases in proportion The objective of this investigation was to develop a to the column length. To demonstrate the scalabil- high throughput HPLC method for the analysis of ity of three different column lengths and particle barbiturates based on an existing slower conven- sizes for the test barbiturates, Figure 2 shows an tional HPLC method. Rapid Resolution (RR) and overlay of three chromatograms. The top chro- Rapid Resolution High Throughput (RRHT) HPLC matogram is the original USP method for pheno- column technology allows one to convert the exist- barbital with the internal standard (caffeine) but ing method into a high throughput method easily with the three additional barbiturates. The USP and straightforwardly to provide a gain in method specifies a 4.6-mm × 250-mm column with productivity. L1 type stationary phase (C18 phase bonded to silica particles) with a minimum resolution of 1.2 For established pharmaceuticals, the starting point [ ]. A ZORBAX Eclipse XDB-C18 column with these for HPLC methods is the United States Pharma- 2 dimensions and 5 µm particles was selected for this copoeia 27 (USP). The USP method for phenobarbi- separation and produced an analysis time of about tal can be found in reference 3. In addition to the 32 minutes. Simply replacing this column for a long acting barbiturate, phenobarbital, we added shorter one, 4.6-mm 100-mm with 3.5 µm an ultra-short (hexobarbital), a short (allobarbital), × particles, reduced analysis time by about a factor and an intermediate (butalbital) acting barbiturate of 2.5 (or 13 min), or by a factor of five using a as standards to demonstrate the power of RR and 4.6-mm 50-mm column with 1.8-µm particles (or RRHT columns. × 7 min). These latter columns provided faster sepa- rations with only a small loss of resolution and are Scalability of Barbiturate Reversed-Phase HPLC Method referred to as RR and RRHT columns, respectively. Scalability refers to the ability of an HPLC method These data show that older methods done on larger to use columns of different diameters and/or particle columns can be easily transferred to RR lengths and particle sizes and still maintain the and RRHT columns without sacrificing separation separation characteristics of the method. Earlier, it integrity. As can be noted in Figure 2, the resolu- was demonstrated that ZORBAX columns with tion of both the 3.5- and the 1.8-µm columns is smaller particles and shorter lengths provide simi- easily within the minimum specification of the USP lar chromatography in a fraction of the time com- method. pared with longer columns and larger particles [3]. 2 Eclipse XDB-C18 1 4.6 × 250 mm, 5 µm mAU P/N 990967-902 60 32 min. Pressure = 174 bar R2,3 = 5.99 40 R4,5 = 4.43 3 20 2 5 4 0 51015202530min Eclipse XDB-C18 4.6 × 100 mm, 3.5 µm (Rapid Resolution, RR) mAU P/N 961967-902 1 Caffeine (ISTD) 40 Pressure = 167 bar 2 Allobarbital 30 13 min. 3 Phenobarbital 20 R2,3 = 4.88 R4,5 = 3.72 4 Butalbital 10 5 Hexobarbital 0 Mobile phase: 60% A, 40% B 51015 A = pH 4.5 Na Acetate B = MeOH Eclipse XDB-C18 Flow: 1 mL/min 4.6 × 50 mm, 1.8 µm (Rapid Resolution HT, RRHT) Injection volume: 2 µL mAU P/N 927975-902 Detector: UV 254 nm 30 Pressure = 291 bar Flow cell: 2 µL, 3 mm flow path 20 R = 4.59 2,3 R = 3.32 10 4,5 7 min. 0 5 Figure 2. RR and RRHT column configurations increase speed and maintain sufficient resolution. Stationary Phase Selectivity as a Function of Particle Size Figure 3 depicts an overlay of the high throughput separation of barbiturates by equivalent 4.6-mm × The productivity increase by changing column 50-mm Eclipse XDB-C18 columns packed with dif- dimensions and particle size is achieved due to the ferent particle sizes. Note selectivity (α) is the reproducibility of the spherical silica particles and same for all three columns, independent of particle bonded phase. The highly uniform manufacturing size. The same selectivity indicates the three differ- process of the ZORBAX base silica, of the organosi- ent sized particles are chemically very similar. The lane bonding process, and of the standardized test- different sized particles can be packed in different ing of the column leads to the ability of the user to column dimensions with predictable and scalable freely substitute columns without suffering selec- results, because they exhibit the same chromato- tivity changes which would ultimately affect reso- graphic characteristics. Figure 3 also demonstrates lution. One way to measure this uniformity is to that as particle size decreases, efficiency increases. compare the selectivity factors among different Note that peak widths decrease, producing better particle sizes. Selectivity (α) is the ratio of the sensitivity (taller peaks), as the particle size retention factors: α2,1 = k'2/k'1 where k'1 is the decreases from 5 to 3.5 to 1.8 µm. adjusted capacity factor for compound 1 and k'2 is the adjusted capacity factor for compound 2. 3 1 t0 = 0.44 min 5 µm α3.2 = 1.20 α4.3 = 1.97 α5.4 = 1.13 P = 73 bar 5 2 3 4 123456min 1 t0 = 0.44 min α α α 3.5 µm 3.2 = 1.20 4.3 = 1.97 5.4 = 1.14 P = 111 bar 2 3 5 4 123456min 1 t0 = 0.46 min α = 1.22 α = 1.94 α = 1.16 1.8 µm 3.2 4.3 5.4 P = 291 bar 2 3 5 4 123456min Columns: Eclipse XDB-C18, 4.6 x 50 mm Peak Widths (min) Mobile phase: 60% A, 40% B 5 µm 3.5 µm 1.8 µm A = pH 4.5 Na Acetate 1 Caffeine (ISTD) 0.043 0.033 0.028 B = MeOH 2 Allobarbital 0.097 0.073 0.058 Flow rate: 1 mL/min 3 Phenobarbital 0.116 0.089 0.072 Injection volume: 2 µL 4 Butalbital 0.213 0.165 0.138 Detector: UV 254 nm 5 Hexobarbital 0.237 0.187 0.167 Flow cell: 2 µL, 3 mm flow path Figure 3. Particle size influence on selectivity and peak width. Optimization of Resolution with RRHT technology diffusion. At lower flow velocities, the contribution from axial diffusion to the H value may be quite A van Deemter plot is often used to depict the high and analysis time quite long. The “C” term changes in column efficiency, usually expressed as relates solute mass transfer from the mobile phase H (or Height Equivalent to a Theoretical Plate, to the stationary phase and vice-versa. It is both HETP), as a function of linear velocity (propor- flow rate and particle size dependent. For a typical tional to flow rate). A typical van Deemter plot is column packed with larger particles, say 5- or shown in Figure 4a. 10-µm, the column will behave like the van Deemter plot in Figure 4a. However, for smaller The shape of the plot can be described by Equation 1: particles such as the 1.8-µm packings, the slope of H = A + B/u + Cu (Equation 1) the van Deemter curve at high linear velocities is much flatter, as depicted in Figure 4b.
Recommended publications
  • Abecarnil/Allobarbital 959 Pharmacopoeias
    Abecarnil/Allobarbital 959 Pharmacopoeias. In Eur. (see p.vii). acamprosate’s action including inhibition of neuronal hyper- maleate in the treatment of anxiety disorders, hiccups, and nau- Ph. Eur. 6.2 (Acamprosate Calcium). A white or almost white excitability by antagonising excitatory amino acids such as sea and vomiting. Acepromazine, as the base, has also been giv- powder. Freely soluble in water; practically insoluble in alcohol glutamate. en in preparations for the management of insomnia. and in dichloromethane. A 5% solution in water has a pH of 5.5 1. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacol- Preparations to 7.0. ogy and clinical potential in the management of alcohol depend- ence after detoxification. Drugs 1997; 53: 1038–53. Proprietary Preparations (details are given in Part 3) Adverse Effects 2. Anonymous. Acamprosate for alcohol dependence? Drug Ther Denm.: Plegicil; Turk.: Plegicil. The main adverse effect of acamprosate is dosage-related diar- Bull 1997; 35: 70–2. Multi-ingredient: Fr.: Noctran. rhoea; nausea, vomiting, and abdominal pain occur less frequent- 3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (suppl ly. Other adverse effects have included pruritus, and occasionally 20): 42–8. a maculopapular rash; bullous skin reactions have occurred rare- 4. Overman GP, et al. Acamprosate for the adjunctive treatment of Aceprometazine (rINN) ly. Depression and fluctuations in libido have also been reported. alcohol dependence. Ann Pharmacother 2003; 37: 1090–9. Hypersensitivity reactions including urticaria, angioedema, and 5. Anton RF, et al. Combined pharmacotherapies and behavioral 16-64 CB; Aceprometazina; Acéprométazine; Aceprometazi- anaphylaxis have been reported very rarely.
    [Show full text]
  • Smumedical Journal
    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.
    [Show full text]
  • Economic and Social Council 1 November 2010
    * United Nations E/CN.7/2010/21 Economic and Social Council 1 November 2010 Original: English Commission on Narcotic Drugs Reconvened fifty-third session Vienna, 2 December 2010 Agenda item 5 Improving the collection, reporting and analysis of data to monitor the implementation of the Political Declaration and Plan of Action on International Cooperation towards an Integrated and Balanced * Strategy to Counter the World Drug Problem Annual report questionnaire: Part Three. Extent and patterns of and trends in drug use∗∗ Note by the Secretariat Pursuant to Commission on Narcotic Drugs resolution 52/12, a meeting of the expert group on data collection was held in Vienna from 12 to 15 January 2010 to review the current data collection tools and collection, collation, analysis and reporting processes. Pursuant to Commission decision 53/2, the Secretariat produced a revised version of the draft annual report questionnaire; the expert group held a meeting in Vienna from 11 to 13 October 2010 to finalize the questionnaire so that the Commission could adopt it at its reconvened fifty-third session. The Secretariat hereby transmits part three of the questionnaire; parts one, two and four will be made available in separate documents (E/CN.7/2010/19, E/CN.7/2010/20 and E/CN.7/2010/22). __________________ * Reissued for technical reasons on 30 January 2012. ∗∗ The present document was submitted after the date required by the 10-week rule as the meeting of the expert group on data collection was held from 11 to 13 October 2010. V.10-57492* (E) *1057492* E/CN.7/2010/21 Annual report questionnaire Part Three.
    [Show full text]
  • Forensic Toxicology Scope of Testing and Detection Limits
    J. RYAN MCMAHON II County Executive INDU GUPTA, MD, MPH MEDICAL EXAMINER’S OFFICE Commissioner of Health FORENSIC TOXICOLOGY LABORATORY CAROLYN H. REVERCOMB, MD, DABP ONONDAGA COUNTY HEALTH DEPARTMENT Chief Medical Examiner KRISTIE BARBA, MS, D-ABFT-FT CENTER FOR FORENSIC SCIENCES Toxicologist Forensic Toxicology Scope of Testing and Detection Limits Table of Contents QUALITATIVE ANALYSES.........................................................................................................2 Volatile Screen by GC/FID .............................................................................................................2 Carbon Monoxide by Microdiffusion..............................................................................................2 Carbon Monoxide by CO-Oximeter ................................................................................................2 Ethylene Glycol by GC/MS.............................................................................................................2 ELISA Buprenorphine by IA for Blood/Urine ................................................................................2 ELISA by IA for Blood ...................................................................................................................3 ELISA by IA for Urine....................................................................................................................4 Gamma Hydroxybutyrate (GHB) by GC/MS..................................................................................5 Gabapentin,
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]
  • 201 PART 329—HABIT-FORMING DRUGS Subpart A—Derivatives
    Food and Drug Administration, HHS § 329.1 section 502(e) of the Federal Food, PART 329ÐHABIT-FORMING DRUGS Drug, and Cosmetic Act. (d) The statement expressing the Subpart AÐDerivatives Designated as amount (percentage) of alcohol present Habit Forming in the product shall be in a size reason- ably related to the most prominent Sec. printed matter on the panel or label on 329.1 Habit-forming drugs which are chem- which it appears, and shall be in lines ical derivatives of substances specified in generally parallel to the base on which section 502(d) of the Federal Food, Drug, the package rests as it is designed to be and Cosmetic Act. displayed. (e) For a product to state in its label- Subpart BÐLabeling ing that it is ``alcohol free,'' it must 329.10 Labeling requirements for habit- contain no alcohol (0 percent). forming drugs. (f) For any OTC drug product in- tended for oral ingestion containing Subpart CÐExemptions over 5 percent alcohol and labeled for use by adults and children 12 years of 329.20 Exemption of certain habit-forming age and over, the labeling shall contain drugs from prescription requirements. the following statement in the direc- AUTHORITY: 21 U.S.C. 352, 353, 355, 371. tions section: ``Consult a physician for use in children under 12 years of age.'' SOURCE: 39 FR 11736, Mar. 29, 1974, unless (g) For any OTC drug product in- otherwise noted. tended for oral ingestion containing over 0.5 percent alcohol and labeled for Subpart AÐDerivatives use by children ages 6 to under 12 years Designated as Habit Forming of age, the labeling shall contain the following statement in the directions § 329.1 Habit-forming drugs which are section: ``Consult a physician for use in chemical derivatives of substances children under 6 years of age.'' specified in section 502(d) of the (h) When the direction regarding age Federal Food, Drug, and Cosmetic in paragraph (e) or (f) of this section Act.
    [Show full text]
  • Prohibited Drugs/Medications in Treatment
    Fourth Judicial Circuit Problem-Solving Courts Prohibited Drugs, Medications, and Substances The list below provides an example of substances and medications that are prohibited in the Problem Solving Courts within the Fourth Judicial Circuit. This is not a complete list. For further clarification of any drug and/or medication not listed please contact the Problem-Solving Courts Office at 904-255-1040. Maintaining a drug free lifestyle is very important in the recovery process. Participants are prohibited from using illegal drugs and alcohol (in any form) and must have over the counter or prescribed medications approved prior to purchasing or ingesting. Any and all “designer stimulants/drugs” that can be purchased legally or illegally are strictly prohibited. Any and all “smoking mixtures” (other than products specifically designated to contain only tobacco- for Adults only) are strictly prohibited. Any and all products sold or marketed under false pretenses with the warning “not for human consumption” are strictly prohibited. Using and/or being in possession of any substance intended to replace an otherwise illegal/prohibited substance is strictly prohibited and may result in immediate expulsion from the program. Examples of Examples of substances prohibited in ALL Problem-Solving Court Programs. For medications, Prohibited Substances/ the brand name is in ( ) if the generic name is also listed. Many over the counter medications Medication Classifications are also listed. For illicit drugs, examples of “street” names are included. Alcohol
    [Show full text]
  • Barbiturates Cassette
    BAR Barbiturates cassette CONTENTS Barbiturates A rapid test for the qualitative detection of Barbiturates in REF 4415240 Barbiturates 40 tests human urine. ONE STEP For professional in vitro diagnostic use only PRINCIPLE La prueba de un solo paso LINEAR BAR Barbiturates cassette (orina) es un inmunoensayo cromatográfico rápido basado en el principio de uniones competitivas. La droga puede estar presente en la muestra de orina, compite frente al conjugado de la misma en los puntos de unión al anticuerpo. Durante la prueba, la muestra de orina migra hacia arriba por acción capilar. Si los Barbitúricos están presentes en la orina en concentraciones inferiores a 300 ng/ml, no saturarán los puntos de unión de los anticuerpos en la tira de la prueba. Las partículas recubiertas de anticuerpos serán capturadas por el conjugado inmovilizado de proteína-Barbitúrico y una línea visible de color aparecerá en la zona de la prueba. Esta línea de color no se formará en la zona de la prueba si el nivel de Barbitúrico está por encima de la del cut-off porque saturará todos los puntos de unión de los anticuerpos de anti-Barbitúricos. Una muestra de orina positiva no generará una línea coloreada en la zona prueba debido a la competencia de la droga, mientras que una muestra de orina negativa o una muestra con una concentración inferior a la del cut-off generará una línea en la zona de la prueba. Para servir como procedimiento de control, una línea coloreada aparecerá siempre en la zona de control si la prueba ha sido realizada correctamente y con un volumen adecuado de muestra.
    [Show full text]
  • English → French → English
    Anglais → Français - A - Acetorphine Acétorphine Acetorphine hydrochloride Chlorhydrate d’acétorphine Acetyl-alpha-methylfentanyl Acétyl-alpha-méthylfentanyl Acetyldihydrocodeine Acétyldihydrocodéine Acetyldihydrocodeine hydrochloride Chlorhydrate d’acétyldihydrocodéine Acetylmethadol Acétylméthadol Alfentanil Alfentanil Alfentanil hydrochloride Chlorhydrate d’alfentanil Allobarbital Allobarbital Allobarbital-aminophenazone Allobarbital-aminophénazone Allylprodine Allylprodine Allylprodine hydrochloride Chlorhydrate d’allylprodine Alphacetylmethadol Alphacétylméthadol Alphacetylmethadol hydrochloride Chlorhydrate d’alphacétylméthadol Alphameprodine Alphaméprodine Alphamethadol Alphaméthadol Alpha-methylfentanyl Alpha-méthylfentanyl Alpha-methylfentanyl hydrochloride Chlorhydrate d’alpha-méthylfentanyl Alpha-methylthiofentanyl Alpha-méthylthiofentanyl Alpha-methylthiofentanyl hydrochloride Chlorhydrate d’alpha-méthylthiofentanyl Alphaprodine Alphaprodine Alphaprodine hydrochloride Chlorhydrate d’alphaprodine Alprazolam Alprazolam Amfepramone Amfépramone Amfepramone glutamate Glutamate d’amfépramone Amfepramone hydrochloride Chlorhydrate d’amfépramone Amfepramone resinate Amfépramone résinate Amfetamine Amfétamine Amfetamine acetylsalicylate Acétylsalicylate d’amfétamine Amfetamine adipate Adipate d’amfétamine Amfetamine p-aminophenylacetate Acétate p-aminophényle d’amfétamine Amfetamine aspartate Aspartate d’amfétamine Amfetamine (4-chlorophenoxy) acetate Acétate (chlorophénoxy-4) d’amfétamine Amfetamine hydrochloride Chlorhydrate d’amfétamine
    [Show full text]
  • 1) Patients Who Abuse Alcohol and Drugs Have Long Been Stereotyped
    Substance Abuse and Dependency This test is based on two books: Treating Alcohol and Drug Problems in Psychotherapy Practice by Arnold M. Washton & Joan E. Zweben and Buzzed: The Straight Facts about the Most Used and Abused Drugs from Alcohol to Ecstasy by Cynthia Kuhn, Scott Swartzwelder & Wilkie Wilson Questions 1 – 50 are based on the book… Treating Alcohol and Drug Problems in Psychotherapy Practice Questions from chapter 1 1) Patients who abuse alcohol and drugs have long been stereotyped by mental health professionals as being a) character disordered b) too resistant c) physically ill d) a liability risk 2) Which is a reason why all practicing therapists should acquire the skills required to address SUDs competently and routinely in their patients? a) applicability of psychotherapy training and skills b) opportunities for early intervention c) private practice opportunities d) all the above 3) All the following patients can benefit from office-based treatment EXCEPT a) individuals who cannot work within the traditional disease model b) individuals whose use of psychoactive substances meets the criteria for serious abuse or dependency c) individuals who prefer absolute privacy and individualized attention d) individuals whose prior experiences with addiction treatment programs have been unhelpful 4) It is acceptable to omit an SUD diagnosis from insurance claims and indicate a mental health diagnosis to meet reimbursement criteria. a) True b) False Questions from chapter 2 5) In which type of use is the substance used to produce specific types of effects to cope with certain types of situations? a) regular b) circumstantial c) experimental d) occasional ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com 6) A diagnosis of dependence requires evidence of tolerance or withdrawal.
    [Show full text]
  • Oregon Health & Science University
    Oregon Health & Science University Department of Pathology Center for Health and Healing Lab Interpretive Summary of Cross-Reactivity of Substances, Duration of Drug Detectability and Adulteration Testing/Specimen Validity Testing in Drugs of Abuse Screening Methods CROSS REACTIVITY Cross-reactivity of structurally similar substances is a problem associated with immunoassay methodologies, resulting in false positive or negative results. Screening technologies are predominantly immunoassay techniques which may prove high sensitivity but are of limited specificity. Manufacturers will test for common potential interfering substances and list these on the package insert, however it is not possible to test every compound. Also some compounds ingested in therapeutic dosage may not cross-react, however when abused in “mega” doses may significantly influence urine immunoassay results. Listed below are potential reactants and cross-reactants with most immunoassay methodologies COMPOUND (Generic Name) COMPOUND (Trade Name) RESULTS/CROSS REACTANTS Acetaminophen (see also Aceta, Acephen, Apacet, Non-reactive Paracetamol) Dapacen, Feverall, Tylenol, Excedrin (combination), Panadol, Tempra Acetaminophen with Codeine (see Tylenol 3, Tylenol with codeine Positive for Opiates (OPI) Potential also Paracetamol with codeine) cross reactants: Dihydrocodeine 6-Acetylmorphine Positive for Opiates (OPI) Acetone Non- reactive Allobarbital Positive for Barbiturates (BAR) Alphenol No known trade names Positive for Barbiturates (BAR) Alprazolam Xanax Positive for
    [Show full text]
  • Drug of Abuse Cut Off Values
    Swedish Laboratory Services – Chemistry Department Drugs of Abuse Concentrations of Compounds that Produce a Result Approximately Equivalent to the Cut-off Value. Drug Category: Amphetamines Compound/Drug Cut-off Unit: ng/mL d-amphetamine 1000 d,l-methamphetamine 1500 d,l-amphetamine 1961 l-methamphetamine 1798 l-amphetamine 8651 MDA 3794 MDMA 13037 MDEA 11192 Unit: μg/mL 4-chloramphetamine 8.2 benzphetamine* 1.3 bupropion 814 chloroquine 3233 l-ephedrine 2240 fenfluramine 75 mephentermine 22.2 methoxyphenamine 231 nor-pseudoephedrine 142 phenmetrazine 6.9 phentermine 16.8 phenylpropanolamine 2000 propranolol 306 d,l-pseudoephedrine 4340 quinacrine 5696 tranylcypromine 85 tyramine 390 * Benzphetamine metabolized to amphetamine and methamphetamine. CHEM.09.909 Advia 1650 Drug of Abuse Cut-off Values Swedish Laboratory Services – Chemistry Department Drug Category: Benzodiazepine Compound/Drug Cut-off Unit: ng/mL alprazolam 65 7-aminoclonazepam 2600 7-aminoflunitrazepam 590 bromazepam 630 chlordiazepoxide 3300 clobazam 260 clonazepam 580 clorazepate * clotiazepam 380 demoxepam 1600 N-desalkylflurazepam 130 N-desmethyldiazepam 110 diazepam 70 estazolam 90 flunitrazepam 140 flurazepam 190 halazepam 110 α-hydroxyalprazolam 100 α-hydroxyalprazolam glucuronide† 110 1-N-hydroxyethlylflurazepam 150 α-hydroxytriazolam 130 ketazolam 100 lorazepam 600 lorazepam glucuronide† >20,000 medazepam 150 midazolam 130 nitrazepam 320 norchlordiazepoxide 2600 oxazepam 250 oxazepam glucuronide† >50,000 prazepam 90 temazepam 140 temazepam glucuronide† 6900 tetrazepam 70 triazolam 130 * Clorazepate degrades rapidly in stomach acid to nordiazepam. Nordiazepam hydroxylates to oxazepam. † The glucuronide metabolite of α-hydroxyalprazolam cross-reacts with this method. Other glucuronide metabolites, such as lorazepam, oxazepam, and temazepam cross-react to a limited extent. The cross-reactivity of other glucuronide metabolites with this method is not known.
    [Show full text]